Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APLT NASDAQ:APRE NASDAQ:KNSA NASDAQ:PHAT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLTApplied Therapeutics$0.10$0.10$0.09▼$1.50$15.86M2.087.28 million shsN/AAPREAprea Therapeutics$0.63$0.77$0.55▼$2.00$7.82M1.559,727 shs18,328 shsKNSAKiniksa Pharmaceuticals International$62.84$56.87$26.27▼$67.53$4.83B0.07650,567 shs619,956 shsPHATPhathom Pharmaceuticals$11.44$10.86$8.02▼$18.31$912.45M0.491.05 million shs936,449 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLTApplied Therapeutics0.00%0.00%0.00%+0.00%-78.54%APREAprea Therapeutics0.00%-7.06%-20.00%-26.61%-66.56%KNSAKiniksa Pharmaceuticals International0.00%-1.74%+6.15%+44.10%+138.66%PHATPhathom Pharmaceuticals0.00%+4.57%+6.72%-1.29%+18.80%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLTApplied Therapeutics$0.10$0.10$0.09▼$1.50$15.86M2.087.28 million shsN/AAPREAprea Therapeutics$0.63$0.77$0.55▼$2.00$7.82M1.559,727 shs18,328 shsKNSAKiniksa Pharmaceuticals International$62.84$56.87$26.27▼$67.53$4.83B0.07650,567 shs619,956 shsPHATPhathom Pharmaceuticals$11.44$10.86$8.02▼$18.31$912.45M0.491.05 million shs936,449 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLTApplied Therapeutics0.00%0.00%0.00%+0.00%-78.54%APREAprea Therapeutics0.00%-7.06%-20.00%-26.61%-66.56%KNSAKiniksa Pharmaceuticals International0.00%-1.74%+6.15%+44.10%+138.66%PHATPhathom Pharmaceuticals0.00%+4.57%+6.72%-1.29%+18.80%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLTApplied Therapeutics 1.67Reduce$1.00870.87% UpsideAPREAprea Therapeutics 2.40Hold$4.07543.46% UpsideKNSAKiniksa Pharmaceuticals International 3.00Buy$68.008.21% UpsidePHATPhathom Pharmaceuticals 2.86Moderate Buy$24.50114.16% UpsideCurrent Analyst Ratings BreakdownLatest KNSA, APRE, PHAT, and APLT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/23/2026KNSAKiniksa Pharmaceuticals International The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$60.00 ➝ $75.007/17/2026APREAprea Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)7/17/2026PHATPhathom Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/13/2026KNSAKiniksa Pharmaceuticals International Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$57.00 ➝ $74.006/29/2026KNSAKiniksa Pharmaceuticals International WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$59.00 ➝ $72.006/23/2026KNSAKiniksa Pharmaceuticals International Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B-) ➝ Hold (C+)6/17/2026KNSAKiniksa Pharmaceuticals International Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy6/17/2026PHATPhathom Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$26.006/8/2026KNSAKiniksa Pharmaceuticals International Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C+) ➝ Buy (B-)5/18/2026KNSAKiniksa Pharmaceuticals International Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/14/2026APREAprea Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$7.00 ➝ $6.00(Data available from 7/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLTApplied Therapeutics$1M15.86N/AN/A$0.49 per share0.21APREAprea Therapeutics$290K26.98N/AN/A$1.52 per share0.42KNSAKiniksa Pharmaceuticals International$677.56M7.14$0.79 per share79.17$7.44 per share8.45PHATPhathom Pharmaceuticals$175.11M5.21N/AN/A($6.14) per share-1.86Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLTApplied Therapeutics-$105.62M-$0.10N/AN/AN/AN/A-340.84%-175.00%N/AAPREAprea Therapeutics-$12.60M-$1.54N/AN/AN/A-4,405.59%-61.03%-50.24%8/11/2026 (Estimated)KNSAKiniksa Pharmaceuticals International$59.01M$0.9069.8235.70N/A9.69%13.26%9.86%7/28/2026 (Estimated)PHATPhathom Pharmaceuticals-$221.25M-$2.12N/A7.33N/A-76.77%N/A-44.29%7/30/2026 (Estimated)Latest KNSA, APRE, PHAT, and APLT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2026Q2 2026APREAprea Therapeutics-$0.23N/AN/AN/A$0.25 millionN/A7/30/2026Q2 2026PHATPhathom Pharmaceuticals-$0.06N/AN/AN/A$72.70 millionN/A7/28/2026Q2 2026KNSAKiniksa Pharmaceuticals International$0.30N/AN/AN/A$226.49 millionN/A5/13/2026Q1 2026APREAprea Therapeutics-$0.23-$0.22+$0.01-$0.22$0.00 millionN/A4/28/2026Q1 2026KNSAKiniksa Pharmaceuticals International$0.18$0.27+$0.09$0.27$206.11 million$214.27 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPLTApplied TherapeuticsN/AN/AN/AN/AN/AAPREAprea TherapeuticsN/AN/AN/AN/AN/AKNSAKiniksa Pharmaceuticals InternationalN/AN/AN/AN/AN/APHATPhathom PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPLTApplied TherapeuticsN/A0.960.96APREAprea TherapeuticsN/A8.928.92KNSAKiniksa Pharmaceuticals InternationalN/A3.793.33PHATPhathom PharmaceuticalsN/A2.212.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLTApplied Therapeutics98.31%APREAprea Therapeutics34.19%KNSAKiniksa Pharmaceuticals International53.95%PHATPhathom Pharmaceuticals99.01%Insider OwnershipCompanyInsider OwnershipAPLTApplied Therapeutics1.60%APREAprea Therapeutics10.49%KNSAKiniksa Pharmaceuticals International51.98%PHATPhathom Pharmaceuticals9.33%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPLTApplied Therapeutics30153.96 million151.50 millionOptionableAPREAprea Therapeutics712.38 million11.08 millionNo DataKNSAKiniksa Pharmaceuticals International22076.94 million36.95 millionOptionablePHATPhathom Pharmaceuticals11079.76 million72.32 millionOptionableKNSA, APRE, PHAT, and APLT HeadlinesRecent News About These CompaniesSummitTX Capital L.P. Purchases 478,065 Shares of Phathom Pharmaceuticals, Inc. $PHAT2 hours ago | marketbeat.comAbsci (NASDAQ:ABSI) vs. Phathom Pharmaceuticals (NASDAQ:PHAT) Financial ContrastJuly 27 at 2:44 AM | americanbankingnews.comPhathom Pharmaceuticals (PHAT) to Post Earnings on ThursdayJuly 23, 2026 | marketbeat.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesJuly 23, 2026 | marketbeat.comPhathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business ...July 20, 2026 | caledonianrecord.comCPhathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026July 20, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND), Phathom Pharmaceuticals (PHAT) and Voyager Therapeutics (VYGR)July 15, 2026 | theglobeandmail.comPhathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 10.2% - Here's What HappenedJuly 13, 2026 | marketbeat.comPhathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)June 23, 2026 | globenewswire.comPhathom Pharmaceuticals, Inc. (PHAT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 9, 2026 | seekingalpha.comPhathom: Why I'm Downgrading To "Sell" Ahead Of CompetitionJune 9, 2026 | seekingalpha.comPhathom Pharmaceuticals (PHAT) Receives a Buy from BarclaysMay 24, 2026 | theglobeandmail.comPhathom Pharmaceuticals to Participate in Upcoming Investor ConferencesMay 22, 2026 | globenewswire.comPhathom Pharmaceuticals Inc Ordinary shares PHATMay 21, 2026 | morningstar.comMPhathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual MeetingMay 20, 2026 | globenewswire.comWhy Phathom Pharmaceuticals, Inc.’s (PHAT) Stock Is Down 6.78%May 17, 2026 | aaii.comAPhathom Pharmaceuticals Signals Strong Growth on Earnings CallMay 16, 2026 | theglobeandmail.comPhathom Pharmaceuticals Announces $130 Million Public OfferingMay 12, 2026 | theglobeandmail.comPhathom Pharmaceuticals (PHAT) Is Up 11.0% After Narrowing Q1 Loss And Reaffirming 2026 Profitability TimelineMay 5, 2026 | finance.yahoo.comHow The Phathom Pharmaceuticals (PHAT) Narrative Is Shifting Around Profitability And Exclusivity RisksMay 5, 2026 | finance.yahoo.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Phathom Pharmaceuticals (PHAT), TELA Bio (TELA) and Nanobiotix (NBTX)May 2, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKNSA, APRE, PHAT, and APLT Company DescriptionsApplied Therapeutics NASDAQ:APLT$0.10 0.00 (0.00%) As of 07/24/2026Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.Aprea Therapeutics NASDAQ:APRE$0.63 0.00 (0.00%) Closing price 07/24/2026 03:47 PM EasternExtended Trading$0.64 +0.00 (+0.63%) As of 07/24/2026 05:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.Kiniksa Pharmaceuticals International NASDAQ:KNSA$62.84 0.00 (0.00%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$62.79 -0.05 (-0.08%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.Phathom Pharmaceuticals NASDAQ:PHAT$11.44 0.00 (0.00%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$11.13 -0.31 (-2.71%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade? Broadcom May Be the Biggest Winner From Alphabet's Earnings CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
